Cynomolgus monkey (pivotal IT tox); FVB mice for ICV safety and fertility/EFD; SMA piglet and SMN-delta7 mouse pharmacology
“In vivo toxicology/safety studies conducted in NHPs utilized a single IT administration of OAV101 at 1.2 x 1013 vg/animal, considered equivalent to the proposed starting clinical dose level for ITVISMA of 1.2x1014 vg/patient based on a 10-fold difference in CSF volume between NHP and human.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗
Why that species
NHP IT delivery transduces 55-79% of ChAT+ spinal motor neurons; CSF volume scaling NHP to human
“IT administration of scAAV9.CBA.SMN demonstrated a 55-79% transduction efficiency of choline acetyltransferase (ChAT) positive motor neurons in NHP spinal cords.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗
Surrogate molecule
No surrogate; research-grade lots (scAAV9.CBA.SMN, OAV101, OAV101B) of the clinical vector, OAV101B most comparable
“The nonclinical development program for ITVISMA evaluated research grade lots, referred to as scAAV9.CBA.SMN, OAV101, and OAV101B, to inform the safety and activity of ITVISMA.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗
Species: general tox
NHP (single IT dose) and newborn FVB mouse (single ICV dose)
“Additional single-dose studies in the newborn Friend Virus B (FVB) mouse strain and NHPs further demonstrated high tolerability to OAV101 or scAAV9.CBA.SMN following ICV or IT administration, respectively, with no major safety signals.”
✓ VerifiedFDA summary basis for approval, p. 16Source ↗
Species: DART
Mouse (FVB; fertility and early embryonic development, single IV dose)
“Fertility and early embryonic development (FEED) studies were conducted in healthy male and female FVB mice administered a single intravenous injection of OAV101B.”
✓ VerifiedFDA summary basis for approval, p. 16Source ↗
Species: carcinogenicity
Not conducted
“No carcinogenicity, genotoxicity, or repeat dosing were conducted for OAV101B.”
✓ VerifiedFDA summary basis for approval, p. 16Source ↗
Surrogate used in
No surrogate molecule; research-grade vector lots (scAAV9.CBA.SMN, OAV101, OAV101B) used
“The nonclinical development program for ITVISMA evaluated research grade lots, referred to as scAAV9.CBA.SMN, OAV101, and OAV101B, to inform the safety and activity of ITVISMA.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗